FIBRONEER-ON: Extension Trial for IPF
Trial Objectives

Participants in this study will be given BI 1015550 whether or not they received the treatment or a placebo (a medication with no active ingredient) in the previous phases of the trial. All participants will receive lung function testing to determine what dose of the treatment is most effective for their symptoms. This data will help researchers determine how effective and safe this treatment is in a longer term than the original study.